S. 935 · 118th Congress · Senate

Fair Accountability and Innovative Research Drug Pricing Act of 2023

Active· Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced
Mar 22, 23
Passed Senate
Pending
Passed House
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

Fair Accountability and Innovative Research Drug Pricing Act of 2023

This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month.

Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug. Manufacturers are subject to civil penalties for failing to comply with the bill's requirements. Additionally, the Food and Drug Administration must post the information on its website.

Action Timeline

2
  1. MAR 22, 2023IntroReferral

    Introduced in Senate

  2. MAR 22, 2023IntroReferral

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Committees

1

Health, Education, Labor, and Pensions Committee

sshr00

Referred: Mar 22, 2023

Active